Curis, Inc. (CRIS)
NASDAQ: CRIS · Real-Time Price · USD
0.582
+0.001 (0.09%)
At close: Apr 28, 2026, 4:00 PM EDT
0.584
+0.002 (0.38%)
After-hours: Apr 28, 2026, 5:41 PM EDT
Curis Revenue
In the year 2025, Curis had annual revenue of $9.44M, down -13.43%. Curis had revenue of $1.14M in the quarter ending December 31, 2025, a decrease of -65.98%.
Revenue (ttm)
$9.44M
Revenue Growth
-13.43%
P/S Ratio
2.46
Revenue / Employee
$393,458
Employees
24
Market Cap
23.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.44M | -1.47M | -13.43% |
| Dec 31, 2024 | 10.91M | 885.00K | 8.83% |
| Dec 31, 2023 | 10.02M | -139.00K | -1.37% |
| Dec 31, 2022 | 10.16M | -487.00K | -4.57% |
| Dec 31, 2021 | 10.65M | -186.00K | -1.72% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Marker Therapeutics | 3.55M |
| OSR Holdings | 2.91M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
| Exicure | 500.00K |
| Lexaria Bioscience | 368.00K |
| Allarity Therapeutics | 320.00K |
CRIS News
- 5 weeks ago - Curis Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Curis Provides Fourth Quarter 2025 Business Update - PRNewsWire
- 6 weeks ago - Curis Transcript: EGM 2026 - Transcripts
- 6 weeks ago - Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026 - PRNewsWire
- 3 months ago - Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - PRNewsWire
- 3 months ago - Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - PRNewsWire
- 5 months ago - Curis Provides Updated Data from its Frontline AML Triplet Study - PRNewsWire
- 5 months ago - Curis to Present at Upcoming 30th Annual SNO Meeting - PRNewsWire